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Abstract Patients with brain tumors including intracra-
nial meningiomas are at increased risk for developing deep
vein thrombosis (DVTs) and suffering thromboembolic
events (VTEs). Many surgeons are concerned that early use
of low dose enoxaparin may increase the risk of intracra-
nial hemorrhage which outweighs the benefit of DVT/VTE
reduction. We aimed to address concerns around the use of
enoxaparin after meningioma resection in the development
of postoperative intracranial hemorrhages and DVT/VTEs.
This is a retrospective review of 86 patients with intra-
cranial meningiomas who underwent craniectomy and
surgical resection of the mass, treated by one attending
surgeon at UCSF Medical Center between 2000 and 2005.
Within 48 h after surgery patients treated 2003–2005 rou-
tinely received enoxaparin therapy unless there was docu-
mented intracranial hemorrhage, lumbar subarachnoid
drain, enoxaparin hypersensitivity, or thrombocytopenia
(n = 24). These were compared to a cohort treated 2000–
2002 who did not receive the drug (n = 62). Exclusion
criteria were prior VTEs or coagulopathies. The groups
were similar in tumor and surgical characteristics. Enox-
aparin therapy did not increase the incidence of intracranial
hemorrhage following surgical meningioma resection and
the incidence of DVTs/VTEs was 0% (n = 0) versus 4.8%
(n = 3) in the non-enoxaparin group. Results did not reach
statistical significance. In this retrospective study, postop-
erative administration of enoxaparin following meningi-
oma resection does not increase the risk of intracranial
hematoma though enoxaparin administration may slightly
decrease the incidence of post-surgical thromboembolic
events. Due to study design and power, we were not able to
demonstrate DVT/VTE reduction with statistical
significance.
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Introduction
Meningiomas are benign intracranial tumors treated by
craniotomy and surgical resection. Postoperative compli-
cations of surgical tumor resection include spontaneous
intracranial hemorrhage [1–3]. However, postoperative
brain tumor patients are also at increased risk of developing
thromboembolic events (VTEs) [4, 5]. It is thought that
thromboembolic events that occur postoperatively follow-
ing resection may be due to the tumor-induced hemostatic
changes resulting in a hypercoagulable state and may be
exacerbated by the post-surgical recovery period when
patients are initially non-ambulatory. Because of this,
patients with brain tumors, including meningiomas are at
increased risk of developing deep vein thrombosis (DVT)
and experiencing venous thromboembolic events (VTE)
[6–9]. DVT and VTEs significantly increase tumor patient
morbidity and mortality and therefore are important aspects
of tumor treatment to address. Prior studies have shown
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that prophylactic treatment with low molecular weight
heparin leads to fewer vascular complications such DVT
and VTEs [10–15]. However, the risk of postoperative
hematoma has been shown to increase with early antico-
agulation [16]. Some studies have evaluated the use of
heparin or enoxaparin with different regimens and different
doses and there is no good consensus for preferred post-
operative anticoagulation regimen. Neurosurgeons are
frequently concerned about the use of anti-coagulation in
the post-craniotomy setting. Meningoma surgery tends to
require extensive bone and soft tissue dissection which
may increase the risk of anti-coagulation treatment-related
post-operative hemorrhagic complications.
Because of the duality of positive and negative effects of
anticoagulation therapy in the post meningioma resection
setting, the use of enoxaparin remains controversial. At our
institution, there is no standard of practice amongst
meningioma surgeons about the use of anti-coagulation
with meningioma resection, although there is Class 1 evi-
dence to support its use in glioma and meningioma patients
post-operatively. One surgeon uses it routinely while the
others do not. We decided to evaluate the use of enoxaparin
by a single surgeon and the associated incidence of post-
operative hematomas and DVT/VTEs in a control cohort
group. Our aim is to address concerns around the use of
enoxaparin after meningioma resection in the development
of postoperative hematomas and thromboembolic events.
Materials and methods
Patient population
Only one surgeon at our institution began using enoxaparin
routinely in 2002 beginning within two days after surgery.
86 patients surgically treated at the University of California
San Francisco Neurosurgery Department between 2000 and
2005 by this surgeon for histologically confirmed menin-
giomas were retrospectively identified from the database.
Patients who underwent surgical resection of intracranial
meningiomas between 2003 and 2005 (after enoxaparin
was routinely administered) were eligible for treatment
with enoxaparin starting within 48 h after surgery. Patients
did not receive enoxaparin therapy if they had a docu-
mented intracranial hemorrhage, presence of a lumbar
subarachnoid drain, hypersensitivity to heparin or enox-
aparin, or thrombocytopenia. The patients who were trea-
ted between 2003 and 2005 and who received enoxaparin
(n = 24) are compared to those who underwent surgical
resection for meningioma between 2000 and 2002, before
enoxaparin was routinely administered, and therefore did
not receive enoxaparin in the post-operative period
(n = 62). Patients were excluded from the study if they had
a prior DVT/VTE, other thromboembolic event, or
coagulopathy.
The average age of patients at initial diagnosis was
56 years for patients who received enoxaparin and those
who did not (range: 30–73 years and 31–80 years respec-
tively). Records were analyzed for symptoms present at
diagnosis, prior chemotherapy or radiotherapy, and pre-
operative embolization to treat the tumor. In addition, we
analyzed tumor characteristics (primary or recurrent tumor,
tumor location and volume) and pathologic diagnosis
(WHO classification of tissue).
Surgical treatment
Between 2000 and 2005, patients underwent craniotomy
and surgical resection of the tumor. Gross total resection
(Simpson Grade I) or near gross total resection (Simpson
Grade II) was performed in most cases studied.
Features of the surgical procedure were noted including
length of procedure and estimated blood loss.
Enoxaparin therapy
Between 2003 and 2005, with start times ranging from
within 24 h up to 48 h after surgery, patients were treated
with enoxaparin delivered as a subcutaneous injection for
between one and seven days. The most common dose of
enoxaparin treatment is 40 mg daily, one patient received a
dose of 30 mg. Of the 24 patients in the treatment group, 8
patients began treatment within 24 h after the operation and
16 initiated treatment between 24 and 48 h after surgery.
The use of post-operative anti-embolic prophylaxis
including TED hose and pneumatic sequential compression
devices (SCD) was also noted.
Statistical analysis
Data were collected through a retrospective review of
charts and were summarized. Records were reviewed for
radiographic evidence of post-operative hematoma and
other complications occurring within the first 30 days of
surgery. Also, records were reviewed for clinical or
radiographic evidence of deep vein thrombosis (DVT) or
venous thromboembolic events (VTEs) following surgical
treatement for meningioma and adjuvant therapy with en-
oxaparin. Only one subject from the treatment group died
prior to 30 days following surgery, all other subjects had
follow-up data for 30 days.
We identified complications as clinical symptoms and
deficits following hemorrhage, radiographic evidence of
DVT, VTE, or hematoma, complications leading to further
surgical or medical treatment, and death. Postoperative
hemorrhages were identified clinically then confirmed and
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classified by CT scan. DVT was diagnosed clinically and




The two populations of patients, those who received en-
oxaparin and those who did not, had similar tumor and
treatment characteristics with the exception of tumor-
associated edema. The tumor qualities and treatment
approach are represented in Table 1. The majority of
meningiomas were WHO grade 1, and the dominant
location of these tumors is in the middle fossa. More
patients who received enoxaparin are known to have had
edema-associated tumors (41.7%) than those who did not
receive enoxaparin therapy (21.0%) (P = 0.45). The
majority of meningiomas in this patient population are
medium to large size and in many cases, treatment included
preoperative embolization followed by resection.
Prior DVT was an exclusion criterion for this study and
therefore 100 percent of patients in the enoxaparin and
non-enoxaparin groups had no history of DVT. All patients
received pneumatic calf compression devices as DVT
prophylaxis until ambulatory.
Postoperative hemorrhages
12.5 percent (n = 3) in the enoxaparin group and 12.9%
(n = 8) in the non-enoxaparin group suffered postoperative
intracranial hemorrhages. Of these, one patient in the
treatment group and 5 patients in the non-treatment group
suffered clinically symptomatic deficits as a result of the
hemorrhage (Table 2).
Of the intracranial hematomas in the group that received
enoxaparin, one was classified as intraparenchymal and
two others as subarachnoid. Of the group that did not
received enoxaparin, postoperative hemorrhages were
classified as intraparenchymal, mixed, and not classified
hematomas (Table 2).
Postoperative DVT/VTEs
There was a slight apparent decrease in the incidence and
percentage of patients with postoperative thromboembolic
events in the enoxaparin group (one and 62.5% respec-
tively) compared to those who did not receive treatment
(five and 67.8% respectively) though these differences did
not achieve statistical significance (P [ 0.5). No patients
receiving enoxaparin experienced clinically diagnosed
VTEs/DVTs. A total of three patients from the non-treat-
ment group experienced DVT/VTE. Two had both pul-
monary embolism and extensive DVTs, involving bilateral
iliac veins and the inferior vena cava in one and the distal
lower extremity in the other. And one patient who did not







1 20 (83.3) 54 (87.1)
2 3 (12.5) 6 (9.7)
3 1 (4.2) 2 (3.2)
Tumor site
Anterior fossa 4 (16.7) 9 (14.5)
Middle fossa 12 (50) 29 (45.2)
Posterior fossa 8 (33.3) 23 (37.1)
Intraventricular 0 1 (1.6)
Associated edema
Yes 10 (41.7) 13 (21.0)
No 8 (33.3) 24 (38.7)
Unknown 6 (25) 25 (40.3)
Preoperative embolization
Yes 9 (37.5) 25 (40.3)
No 15 (62.5) 37 (59.7)
Simpson grade resection
0 0 2 (3.2)
1 6 (25) 16 (25.8)
2 10 (41.7) 20 (32.3)
3 3 (12.5) 12 (19.4)
4 0 2 (3.2)
5 0 1 (1.6)
Unknown 5 (20.8) 9 (14.5)
Primary versus reoperation
Primary 19 (79.2) 55 (88.7)
Reoperation 5 (20.8) 7 (11.3)
Table 2 Postoperative hemorrhage characteristics in the enoxaparin







Postoperative hemorrhage 3 (12.5) 8 (12.9)
Symptomatic hemorrhage 1 (4.2) 5 (8.1)
Hemorrhage classification
Intraparenchymal 1 (4.2) 2 (3.2)
Subdural 0 0
Subarachnoid 2 (8.3) 0
Mixed 0 3 (4.8)
Not classified 0 3 (4.8)
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receive enoxaparin had an extensive right lower extremity
DVT alone.
In addition, three patients total suffered intracranial
arterial embolic strokes, one in the enoxaparin group and
two in the non-enoxaparin group. Table 3 represents all
reported postoperative hemorrhage-related, thrombotic,
and other complications. Reported complications were
greater in the non-treatment group except neurologic,
genitourinary (UTI and acute renal failure), hematologic
(anemia), and the one death (due to renal failure) P [ 0.5.
Discussion
No consensus about postoperative administration of enox-
aparin as thromboembolic prophylaxis following
meningioma resection has been reached thus far. The
biggest confounding complication is undoubtedly pub-
lished evidence of increased risk of postoperative intra-
cranial hemorrhage with the administration of a low
molecular weight heparin [17]. Other contributing factors
may include surgeon preference as well as conflicting
studies some of which support anticoagulation in decreas-
ing the risk of DVT and PE and others which show no
difference in their occurrences [18, 19]. Individual patient
characteristics such as age, preexisting compromise of
vascular integrity, use of lumbar drains or coagulopathies
make each meningioma resection unique and therefore may
prolong controversy in the field around adjuvant enoxap-
arin administration post meningioma resection [1, 20, 21].
Perhaps a large multi-center, randomized control trial is
necessary to conclusively establish practice guidelines.
Table 3 Reported complications following surgical resection of meningioma
Reported complications Enoxaparin No enoxaparin
Number of pts
with comps






Percentage of all pts
who did not receive enox
Number
of events
Hemorrhage-related 1 4.2 2 5 8.1 8
Progressive somnolence 1 4.2 1 0 0 0
Altered mental status 0 0 0 1 1.6 1
Language impairment 0 0 0 0 0 0
Seizure 0 0 0 2 3.2 2
Headache 0 0 0 1 1.6 1
Hematoma evacuation 1 4.2 1 2 3.2 2
Craniectomy 0 0 0 2 3.2 2
Venous thrombotic events 0 0 0 3 4.8 5
DVT 0 0 0 3 4.8 3
Pulmonary embolism 0 0 0 2 3.2 2
Intracranial embolic infarct 1 4.2 1 2 3.2 2
Surgery-related 3 12.5 3 12 19.4 19
CSF leak 1 4.2 1 0 0 0
Scalp/wound infection 2 8.3 2 2 3.2 2
Pseudomeningocele 0 0 0 3 4.8 3
Pneumocephalus 0 0 0 1 1.6 1
Hydrocephalus 0 0 0 8 12.9 8
VP shunt placement 0 0 0 5 8.1 5
Constitutional 0 0 0 1 1.6 1
Neurologic 13 54.2 20 29 46.8 41
Pulmonary 1 4.2 1 5 8.1 5
GU 2 8.3 2 0 0 0
Hematologic 1 4.2 1 0 0 0
Cardiac 0 0 0 1 1.6 1
Death 1 4.2 1 0 0 0
Other 0 0 0 4 6.5 4
Total 15 62.5 31 42 67.8 86
Pts patients, comps complications, enox enoxaparin
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In agreement with many and in direct opposition to
other studies, we have found that postoperative adminis-
tration of enoxaparin following resection of meningiomas
is consistent with a lower rate of clinically significant
thromboembolic events such as DVT or VTEs however we
were not able to demonstrate this definitively. Though this
retrospective study was not designed or powered to eval-
uate the reduction in thromboembolic risk (retrospective,
cohort design), we have demonstrated that the incidence of
DVTs/VTEs with enoxaparin therapy does not increase
over non-treatment. Prior studies showing a reduction in
thromboembolic events in neurosurgical patients include
those of Frim et al. 1992 (low-dose heparin plus pneumatic
compression boots) and Agnelli et al. 1998 while those of
Barnett et al. 1977, Goldhaber et al. 2002 and Bostro¨m
et al. 1986 do not. Of the studies that did show a difference
all were prospective randomized controlled trials with
P = 0.020 and P = 0.04, respectively. Similarly, the
negative studies all were prospective randomized trials.
This lack of agreement with seemingly properly designed
and conducted trials, has raised questions for surgeons
about the external validity and applicability of the con-
clusions from one study alone. Our control (non-enoxapa-
rin) and study (enoxaparin) populations were similar in
terms of WHO grade, tumor location, associated edema,
preoperative embolization, Simpson grade resection and
newly diagnosed or recurrent tumor.
In addition, our investigation suggests that for the popu-
lation studied, postoperative enoxaparin administration does
not cause an increase in the number of postoperative intra-
cranial hemorrhages nor does it increase the percentage of
symptomatic intracranial bleeds. In fact, the percentage of
hemorrhage and symptomatic hemorrhage was greater in the
non-enoxaparin control group though was not statistically
significant. This is critical information when considering the
initiation of enoxaparin therapy post meningioma resection.
For patients who may benefit from the anticoagulation
properties of enoxaparin, it is critical to understand that they
may not be at increased risk of developing intracranial
hemorrhages if therapy is begun. At our institution for the
senior authors cases enoxaparin is begun the morning of the
second day following surgery if no contraindications to its
use exist. Frequently postoperative scanning is done within
48 h or earlier if there is a clinical problem and radiographic
evidence of hemorrhage may influence the decision on
whether or not to start prophylactic therapy.
Conclusions
Our study suggests that there is no significant increased
risk of postoperative hemorrhage in patients who receive
enoxaparin compared to those who do not. The overall
incidence of a symptomatic hemorrhage requiring treat-
ment is thankfully low in both treated and non-treated
groups. We were not, however, able to conclusively dem-
onstrate statistically significant improvement in DVT/
VTEs with enoxaparin therapy due to limitations such as
small sample size, retrospective design, and unknown
patient characteristics that cannot be screened for. Another
limitation of this retrospective study is that time to first
ambulation is not documented and therefore was not
available for all patients. Although antiembolic prophylaxis
such as SCD and TED were routinely used in all patients
until ambulatory, early ambulation is known to decrease
the incidence of DVT/VTE in postoperative paitents. These
limitations contribute to the dispute regarding enoxaparin
use in postoperative meningioma resection patients. Our
results suggest an agreement with prior studies reporting
that the frequency of thromboembolic events is lower in
meningioma patients who receive enoxaparin therapy
within the first 48 h after surgical resection and offer some
support for the routine administration of enoxaparin fol-
lowing meningioma resection to decrease the incidence of
postoperative thromboembolic events.
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